Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results (Q35504499)
Jump to navigation
Jump to search
scientific article published on 21 April 2015
| Language | Label | Description | Also known as |
|---|---|---|---|
| English | Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results |
scientific article published on 21 April 2015 |
Statements
1 reference
Survival with AGS-003, an autologous dendritic cell-based immunotherapy, in combination with sunitinib in unfavorable risk patients with advanced renal cell carcinoma (RCC): Phase 2 study results (English)
1 reference
Asim Amin
1 reference
Arkadiusz Z Dudek
1 reference
Theodore F Logan
1 reference
Raymond S Lance
1 reference
Jeffrey M Holzbeierlein
1 reference
Jennifer J Knox
1 reference
Viraj A Master
1 reference
Sumanta K Pal
1 reference
Wilson H Miller
1 reference
Lawrence I Karsh
1 reference
Irina Y Tcherepanova
1 reference
Mark A DeBenedette
1 reference
W Lee Williams
1 reference
Douglas C Plessinger
1 reference
Charles A Nicolette
1 reference
Robert A Figlin
1 reference
21 April 2015
1 reference
1 reference
21 April 2015
1 reference
1 reference
1 reference
1 reference
1 reference
Identifiers
1 reference